United Therapeutics (UTHR) Cash from Investing Activities (2009 - 2026)

United Therapeutics has disclosed Cash from Investing Activities across 18 years of filings, most recently posting $743.7 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $743.7 million, up 551.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $357.1 million (up 173.96% YoY), and the FY2025 annual result was -$551.3 million, down 232.14% from the prior year.
• Cash from Investing Activities came in at $743.7 million for Q1 2026 at United Therapeutics, up from -$227.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $743.7 million in Q1 2026 to a low of -$359.2 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$164.7 million (2025), against an average of -$54.2 million.
• Across the five-year window, Cash from Investing Activities sank 5601.59% in 2022 and jumped 551.55% in 2026, its largest moves.
• United Therapeutics' Cash from Investing Activities stood at -$189.3 million in 2022, then surged by 122.24% to $42.1 million in 2023, then sank by 392.64% to -$123.2 million in 2024, then tumbled by 84.74% to -$227.6 million in 2025, then soared by 426.76% to $743.7 million in 2026.
• The last three Cash from Investing Activities figures came in at $743.7 million (Q1 2026), -$227.6 million (Q4 2025), and $140.9 million (Q3 2025), per Business Quant data.